ON Holding AG vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? ON Holding AG trades at $34.83 (market cap $11.38B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.46 (market cap $2.27B). The key difference: ON Holding AG is far larger — about 5× SELLAS Life Sciences Group Inc. Common Stock's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, ON Holding AG nearer its low. Which is the better fit depends on your goals.
| ONON | SLS | |
|---|---|---|
Market Cap | $11.38B | $2.27B |
Volume | 13,732,872 | 4,179,659 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.63 | $15.46 |
52-Week Low | $26.76 | $1.39 |
Typical Hold Time | 22 Days | — |
Enterprise Value | $10.54B | $2.14B |
Signals from Pluang's Aura AI — not financial advice
ONON trades at $34.79, up 4.73% today, reflecting strong momentum. The stock shows bullish technical signals with support at $33 and resistance at $35. Fundamentally, the company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $0.44 exceeding expectations. Revenue reached $3.01 billion in 2025, with a net income margin of 12.3%. Recent news highlights a $1 billion share buyback plan and ambitious 2029 targets.
The outlook is positive, driven by earnings growth, strategic expansion, and strong analyst support. Key risks include competitive pressures and market volatility. Analysts maintain a consensus buy rating with a $42.26 price target, suggesting potential upside from current levels.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →